STOK
Stoke Therapeutics Inc

1,013
Mkt Cap
$1.73B
Volume
557,698.00
52W High
$38.69
52W Low
$5.35
PE Ratio
45.98
STOK Fundamentals
Price
$30.34
Prev Close
$31.07
Open
$30.56
50D MA
$31.16
Beta
1.31
Avg. Volume
872,643.36
EPS (Annual)
-$1.65
P/B
5.43
Rev/Employee
$285,585.94
Loading...
Loading...
News
all
press releases
Stoke Therapeutics (NASDAQ:STOK) Trading 6.2% Higher - Here's What Happened
Stoke Therapeutics (NASDAQ:STOK) Trading Up 6.2% - Here's What Happened...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Stoke Therapeutics, Inc. $STOK is Skorpios Trust's Largest Position
Skorpios Trust lowered its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 30.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The...
MarketBeat·10d ago
News Placeholder
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire·15d ago
News Placeholder
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Moderate Buy" by Analysts
Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) have received an average recommendation of "Moderate Buy" from the ten brokerages that are currently covering the firm, MarketBeat...
MarketBeat·15d ago
News Placeholder
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down - Here's What Happened
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down - Here's What Happened...
MarketBeat·19d ago
News Placeholder
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $36.00 at Wedbush
Wedbush lifted their price objective on Stoke Therapeutics from $32.00 to $36.00 and gave the company an "outperform" rating in a research note on Monday...
MarketBeat·19d ago
News Placeholder
8 Analysts Have This To Say About Stoke Therapeutics
read more...
Benzinga·19d ago
News Placeholder
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire·25d ago
News Placeholder
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $35.00 at Chardan Capital
Chardan Capital lifted their price target on shares of Stoke Therapeutics from $24.00 to $35.00 and gave the company a "buy" rating in a report on Monday...
MarketBeat·26d ago
News Placeholder
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Buy" by Analysts
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has earned a consensus rating of "Buy" from the ten analysts that are presently covering the company, MarketBeat reports. Two investment...
MarketBeat·1mo ago
<
1
2
...
>

Latest STOK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.